Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>Romosozumab appears to outperform alendronate for fracture prevention in women with osteoporosis, but an increase in cardiovascular adverse events has derailed FDA approval.</p>

Possible Adverse Cardiovascular Events Slow Osteoporosis Drug Approval Process